What is it about?
Type 1 diabetes and LADA are autoimmune diseases with loss of immune tolerance and reduced function and number of beta cells. DPP-inhibitors and vitamin D3 have effects about immune system and beta cells, and therefore may have beneficial effects when associated to treat autoimmune diabetes.
Featured Image
Photo by Kate on Unsplash
Why is it important?
DPP-inhibitors and vitamin D3 are safe medicines and with little adverse effects, with effects about immune system and beta cells can be a new treatment to autoimmune diabetes because this association is not an imunusupression treatment, but an immunomodulation together with beta cells stimulation. In addition, both medicines decrease beta cells apoptosis, that is increased in the type 1 diabetes and LADA.
Perspectives
We believe that this association when used in new-onset type 1 diabetes and new-onset LADA can help to preserve beta cell function with safety and low cost. In addition, can help to prevent other autoimmune diseases that can occur togehther with autoimmune diabetes.
MD,PhD MARCELO MAIA PINHEIRO
Univag - University Center
Read the Original
This page is a summary of: Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future, International Immunopharmacology, April 2018, Elsevier,
DOI: 10.1016/j.intimp.2018.02.003.
You can read the full text:
Contributors
The following have contributed to this page
